

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**16-620 / S-062**

**Trade Name:     Macrochantin**

**Generic Name:   Nitrofurantoin macrocrystals**

**Sponsor:         Proctor and Gamble Pharmaceuticals, Inc.**

**Approval Date:   July 16, 1997**

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*

**16-620 / S-062**

## CONTENTS

### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Approvable Letter</b>	
<b>Labeling</b>	<b>X</b>
<b>Summary Review</b>	
<b>Officer/Employee List</b>	
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Medical Review(s)</b>	
<b>Chemistry Review(s)</b>	
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	
<b>Statistical Review(s)</b>	
<b>Microbiology Review(s)</b>	<b>X</b>
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**16-620 / S-062**

**APPROVAL LETTER**

NDA 8-693/S-030  
NDA 16-620/S-062  
NDA 20-064/S-008

Procter & Gamble Pharmaceuticals  
Attention: Arthur C. Ilse  
Regulatory Affairs  
Sharon Woods Technical Center  
11450 Grooms Road  
Cincinnati, OH 45242-1434

JUL 16 1997

Dear Mr. Ilse:

Please refer to your supplemental new drug applications dated August 20, 1996, received August 21, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Furadantin® (nitrofurantoin) Tablets, Macrochantin® (nitrofurantoin macrocrystals) Capsules, and Macrobid® (nitrofurantoin monohydrate/macrocrystals) Capsules.

These supplemental applications provide for revisions to the **CLINICAL PHARMACOLOGY** section, **Susceptibility Tests** subsection, and the **REFERENCES** section of the labeling in response to the Agency's letter dated August 28, 1995.

We have completed the review of these supplemental applications, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the draft labeling in the submissions dated August 20, 1996. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labelings (FPL's) must be identical to the draft labeling submitted on August 20, 1996.

Please submit 20 copies of the FPL's as soon as they are available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved supplemental NDAs 8-693/S-030, 16-620/S-062, and 20-064/S-008. Approval of these submissions by the FDA is not required before the labelings are used.

Should additional information relating to the safety and effectiveness of the drugs become available, revision of these labelings may be required.

Should a letter communicating important information about these drug products (i.e., a "Dear Doctor" letter) be issued to physicians and others responsible for patient care, we request that

NDA 8-693/S-030  
NDA 16-620/S-062  
NDA 20-064/S-008  
Page 2

you submit a copy of the letter to these NDA's and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20852-9787

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Beth Duvall-Miller, Project Manager, at (301) 827-2120.

Sincerely yours,



Gary K. Chikami, M.D.

Acting Director

Division of Anti-Infective Drug Products

Office of Drug Evaluation IV

Center for Drug Evaluation and Research

NDA 8-693/S-030  
NDA 16-620/S-062  
NDA 20-064/S-008  
Page 3

cc:

Original NDA's 8-693, 16-620, 20-064  
HFD-520/Div. files  
HFD-520/CSO/B. Duvall-Miller  
HFD-520/SCSO/J. Bona  
HFD-520/Micro/F. Marsik  
HFD-520/TLMicro/A. Sheldon  
HFD-520/MO/R. Viraraghavan  
DISTRICT OFFICE  
HF-2/Medwatch (with labeling)  
HFD-92/DDM-DIAB (with labeling)  
HFD-40/DDMAC (with labeling)  
HFD-613/OGD (with labeling)  
HFD-560/OTC (with labeling - for OTC Drug Products Only)  
HFI-20/Press Office (with labeling)

Concurrence:

HFD-520/SCSO/J. Bona *J. Bona 7/18/97*  
HFD-520/Micro/F. Marsik *F. Marsik 7/11/97*  
HFD-520/TLMicro/A. Sheldon *A. Sheldon 7/11/97*  
HFD-520/SMO/J. Soreth *J. Soreth 7/11/97*  
HFD-520/ActDivDir/G. Chikami *G. Chikami 7/11/97*

Drafted by: bdm/June 11, 1997/M:\SUPPAP\8693.030

Initialed by:

final: *bdm 7/11/97*

APPROVAL (AP)

**CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***

**16-620 / S-062**

**LABELING**


## Macrodantin (nitrofurantoin macrocrystals)

### Macrodantin®

(nitrofurantoin macrocrystals)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of **Macrodantin** and other antibacterial drugs, **Macrodantin** should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

**DESCRIPTION:** **Macrodantin** (nitrofurantoin macrocrystals) is a synthetic chemical of controlled crystal size. It is a stable, yellow, crystalline compound. **Macrodantin** is an antibacterial agent for specific urinary tract infections. It is available in 25 mg, 50 mg, and 100 mg capsules for oral administration.



1-[[5-NITRO-2-FURANYL]METHYLENE]AMINO]-2, 4-IMIDAZOLIDINEDIONE

**Inactive Ingredients:** Each capsule contains edible black ink, gelatin, lactose, starch, talc, titanium dioxide, and may contain FD&C Yellow No. 6 and D&C Yellow No. 10.

**CLINICAL PHARMACOLOGY:** **Macrodantin** is a larger crystal form of **Furadantin**® (nitrofurantoin). The absorption of **Macrodantin** is slower and its excretion somewhat less when compared to **Furadantin**. Blood concentrations at therapeutic dosage are usually low. It is highly soluble in urine, to which it may impart a brown color.

Following a dose regimen of 100 mg q.i.d. for 7 days, average urinary drug recoveries (0-24 hours) on day 1 and day 7 were 37.9% and 35.0%.

Unlike many drugs, the presence of food or agents delaying gastric emptying can increase the bioavailability of **Macrodantin**, presumably by allowing better dissolution in gastric juices.

**Microbiology:** Nitrofurantoin is bactericidal in urine at therapeutic doses. The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules. As a result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria. Development of resistance to nitrofurantoin has not been a significant problem since its introduction in 1953. Cross-resistance with antibiotics and sulfonamides has not been observed, and transferable resistance is, at most, a very rare phenomenon.

## Macrofantin (nitrofantoin macrofantals)

Nitrofantoin, in the form of **Macrofantin**, has been shown to be active against most strains of the following bacteria both *in vitro* and in clinical infections (see **INDICATIONS AND USAGE**):

### Gram-Positive Aerobes

*Staphylococcus aureus*  
Enterococci (e.g., *Enterococcus faecalis*)

### Gram-Negative Aerobes

*Escherichia coli*

NOTE: Some strains of *Enterobacter* species and *Klebsiella* species are resistant to nitrofantoin.

Nitrofantoin also demonstrates *in vitro* activity against the following microorganisms, although the clinical significance of these data with respect to treatment with **Macrofantin** is unknown:

### Gram-Positive Aerobes

Coagulase-negative staphylococci  
(including *Staphylococcus epidermidis* and  
*Staphylococcus saprophyticus*)  
*Streptococcus agalactiae*  
Group D streptococci  
Viridans group streptococci

### Gram-Negative Aerobes

*Citrobacter amalonaticus*  
*Citrobacter diversus*  
*Citrobacter freundii*  
*Klebsiella oxytoca*  
*Klebsiella ozaenae*

Nitrofantoin is not active against most strains of *Proteus* species or *Serratia* species. It has no activity against *Pseudomonas* species.

Antagonism has been demonstrated *in vitro* between nitrofantoin and quinolone antimicrobial agents. The clinical significance of this finding is unknown.

### Susceptibility Tests:

#### Dilution techniques:

Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on a dilution method<sup>1</sup> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of nitrofantoin powder. The MIC values should be interpreted according to the following criteria:

<u>MIC (<math>\mu\text{g/mL}</math>)</u>	<u>Interpretation</u>
$\leq 32$	Susceptible (S)
64	Intermediate (I)
$\geq 128$	Resistant (R)

## Macrodantin (nitrofurantoin macrocrystals)

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard nitrofurantoin powder should provide the following MIC values:

<u>Microorganism</u>	<u>MIC (µg/mL)</u>
<i>E. coli</i> ATCC 25922	4-16
<i>S. aureus</i> ATCC 29213	8-32
<i>E. faecalis</i> ATCC 29212	4-16

### Diffusion techniques:

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<sup>2</sup> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 300 µg nitrofurantoin to test the susceptibility of microorganisms to nitrofurantoin.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 300 µg nitrofurantoin disk should be interpreted according to the following criteria:

<u>Zone Diameter (mm)</u>	<u>Interpretation</u>
≥ 17	Susceptible (S)
15-16	Intermediate (I)
≤ 14	Resistant (R)

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for nitrofurantoin.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 300 µg nitrofurantoin disk should provide the following zone diameters in these laboratory test quality control strains:

<u>Microorganism</u>	<u>Zone Diameter (mm)</u>
<i>E. coli</i> ATCC 25922	20-25
<i>S. aureus</i> ATCC 25923	18-22

**INDICATIONS AND USAGE:** Macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of *Escherichia coli*, enterococci, *Staphylococcus aureus*, and certain susceptible strains of *Klebsiella* and *Enterobacter* species.

Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses.

## **Macrochantin** (nitrofurantoin macrocrystals)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of **Macrochantin** and other antibacterial drugs, **Macrochantin** should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Nitrofurantoin lacks the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with **Macrochantin** are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with **Macrochantin**, other therapeutic agents with broader tissue distribution should be selected. In considering the use of **Macrochantin**, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.

**CONTRAINDICATIONS:** Anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug.

Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38-42 weeks' gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age.

**Macrochantin** is also contraindicated in those patients with known hypersensitivity to nitrofurantoin.

**WARNINGS: ACUTE, SUBACUTE, OR CHRONIC PULMONARY REACTIONS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH NITROFURANTOIN. IF THESE REACTIONS OCCUR, MACROCHANTIN SHOULD BE DISCONTINUED AND APPROPRIATE MEASURES TAKEN. REPORTS HAVE CITED PULMONARY REACTIONS AS A CONTRIBUTING CAUSE OF DEATH.**

**CHRONIC PULMONARY REACTIONS (DIFFUSE INTERSTITIAL PNEUMONITIS OR PULMONARY FIBROSIS, OR BOTH) CAN DEVELOP INSIDIOUSLY. THESE REACTIONS OCCUR RARELY AND GENERALLY IN PATIENTS RECEIVING THERAPY FOR SIX MONTHS OR LONGER. CLOSE MONITORING OF THE PULMONARY CONDITION OF PATIENTS RECEIVING LONG-TERM THERAPY IS WARRANTED AND REQUIRES THAT THE BENEFITS OF THERAPY BE WEIGHED AGAINST POTENTIAL RISKS (SEE RESPIRATORY REACTIONS).**

Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been reported. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, the drug should be withdrawn immediately and appropriate measures should be taken.

## **Macrochantin** (nitrofurantoin macrocrystals)

Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating disease may enhance the occurrence of peripheral neuropathy. Patients receiving long-term therapy should be monitored periodically for changes in renal function.

Optic neuritis has been reported rarely in postmarketing experience with nitrofurantoin formulations.

Cases of hemolytic anemia of the primaquine-sensitivity type have been induced by nitrofurantoin. Hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Hemolysis is an indication for discontinuing **Macrochantin**; hemolysis ceases when the drug is withdrawn.

**Pseudomembranous colitis has been reported with nearly all antibacterial agents, including nitrofurantoin, and may range from mild to life threatening. Therefore, it is important to consider this diagnosis in patients with diarrhea subsequent to the administration of antibacterial agents.**

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is one primary cause of antibiotic-associated colitis.

After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.

**PRECAUTIONS: Information for Patients:** Patients should be advised to take **Macrochantin** with food to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy.

Many patients who cannot tolerate microcrystalline nitrofurantoin are able to take **Macrochantin** without nausea.

Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking **Macrochantin**.

Patients should be counseled that antibacterial drugs including **Macrochantin** should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When **Macrochantin** is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by **Macrochantin** or other antibacterial drugs in the future.

## Macrochantin (nitrofurantoin macrocrystals)

**General:** Prescribing **Macrochantin** in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**Drug Interactions:** Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.

Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.

**Drug/Laboratory Test Interactions:** As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict's and Fehling's solutions but not with the glucose enzymatic test.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks. Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF<sub>1</sub> mice revealed no evidence of carcinogenicity.

Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F<sub>1</sub> mice as shown by increased incidences of tubular adenomas, benign mixed tumors, and granulosa cell tumors of the ovary. In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, osteosarcomas of the bone, and neoplasms of the subcutaneous tissue. In one study involving subcutaneous administration of 75 mg/kg nitrofurantoin to pregnant female mice, lung papillary adenomas of unknown significance were observed in the F1 generation.

Nitrofurantoin has been shown to induce point mutations in certain strains of *Salmonella typhimurium* and forward mutations in L5178Y mouse lymphoma cells. Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture. Results of the sex-linked recessive lethal assay in *Drosophila* were negative after administration of nitrofurantoin by feeding or by injection. Nitrofurantoin did not induce heritable mutation in the rodent models examined.

The significance of the carcinogenicity and mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown.

## **Macrochantin** (nitrofurantoin macrocrystals)

The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug. Doses of 10 mg/kg/day or greater in healthy human males may, in certain unpredictable instances, produce a slight to moderate spermatogenic arrest with a decrease in sperm count.

### **Pregnancy:**

**Teratogenic effects:** Pregnancy Category B. Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin. In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and a low incidence of minor and common malformations were observed. However, at 25 times the human dose, fetal malformations were not observed; the relevance of these findings to humans is uncertain. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Non-teratogenic effects:** Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary adenomas in the F1 generation mice at doses 19 times the human dose on a mg/kg basis. The relationship of this finding to potential human carcinogenesis is presently unknown. Because of the uncertainty regarding the human implications of these animal data, this drug should be used during pregnancy only if clearly needed.

**Labor and Delivery:** See **CONTRAINDICATIONS**.

**Nursing Mothers:** Nitrofurantoin has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see **CONTRAINDICATIONS**).

**Pediatric Use:** **Macrochantin** is contraindicated in infants below the age of one month (see **CONTRAINDICATIONS**).

**Geriatric Use:** Clinical studies of **Macrochantin** did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Spontaneous reports suggest a higher proportion of pulmonary reactions, including fatalities, in elderly patients; these differences appear to be related to the higher proportion of elderly patients receiving long-term nitrofurantoin therapy. As in younger patients, chronic pulmonary reactions generally are observed in patients receiving therapy for six months or longer (see **WARNINGS**). Spontaneous reports also suggest an increased proportion of severe hepatic reactions, including fatalities, in elderly patients (see **WARNINGS**).

In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy should be considered when prescribing **Macrochantin**. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications (see

**Macrochantin** (nitrofurantoin macrocrystals)

**CONTRAINDICATIONS).** Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

**ADVERSE REACTIONS:**

**Respiratory:**

**CHRONIC, SUBACUTE, OR ACUTE PULMONARY HYPERSENSITIVITY REACTIONS MAY OCCUR.**

**CHRONIC PULMONARY REACTIONS OCCUR GENERALLY IN PATIENTS WHO HAVE RECEIVED CONTINUOUS TREATMENT FOR SIX MONTHS OR LONGER. MALAISE, DYSPNEA ON EXERTION, COUGH, AND ALTERED PULMONARY FUNCTION ARE COMMON MANIFESTATIONS WHICH CAN OCCUR INSIDIOUSLY. RADIOLOGIC AND HISTOLOGIC FINDINGS OF DIFFUSE INTERSTITIAL PNEUMONITIS OR FIBROSIS, OR BOTH, ARE ALSO COMMON MANIFESTATIONS OF THE CHRONIC PULMONARY REACTION. FEVER IS RARELY PROMINENT.**

**THE SEVERITY OF CHRONIC PULMONARY REACTIONS AND THEIR DEGREE OF RESOLUTION APPEAR TO BE RELATED TO THE DURATION OF THERAPY AFTER THE FIRST CLINICAL SIGNS APPEAR. PULMONARY FUNCTION MAY BE IMPAIRED PERMANENTLY, EVEN AFTER CESSATION OF THERAPY. THE RISK IS GREATER WHEN CHRONIC PULMONARY REACTIONS ARE NOT RECOGNIZED EARLY.**

In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form. Upon cessation of therapy, recovery may require several months. If the symptoms are not recognized as being drug-related and nitrofurantoin therapy is not stopped, the symptoms may become more severe.

Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation or pleural effusion on x-ray, and eosinophilia. Acute reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Resolution often is dramatic (see **WARNINGS**).

Changes in EKG (e.g., non-specific ST/T wave changes, bundle branch block) have been reported in association with pulmonary reactions.

Cyanosis has been reported rarely.

**Hepatic:** Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely (see **WARNINGS**).

**Neurologic:** Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating diseases may increase the possibility of peripheral neuropathy (see **WARNINGS**).

Asthenia, vertigo, nystagmus, dizziness, headache, and drowsiness also have been reported with the use of nitrofurantoin.

## **Macrochantin** (nitrofurantoin macrocrystals)

Benign intracranial hypertension (pseudotumor cerebri), confusion, depression, optic neuritis, and psychotic reactions have been reported rarely. Bulging fontanel, as a sign of benign intracranial hypertension in infants, have been reported rarely.

**Dermatologic:** Exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome) have been reported rarely. Transient alopecia also has been reported.

**Allergic:** A lupus-like syndrome associated with pulmonary reactions to nitrofurantoin has been reported. Also, angioedema; maculopapular, erythematous, or eczematous eruptions; pruritus; urticaria; anaphylaxis; arthralgia; myalgia; drug fever; and chills have been reported. Hypersensitivity reactions represent the most frequent spontaneously-reported adverse events in worldwide postmarketing experience with nitrofurantoin formulations.

**Gastrointestinal:** Nausea, emesis, and anorexia occur most often. Abdominal pain and diarrhea are less common gastrointestinal reactions. These dose-related reactions can be minimized by reduction of dosage. Sialadenitis and pancreatitis have been reported. There have been sporadic reports of pseudomembranous colitis with the use of nitrofurantoin. The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment (see **WARNINGS**).

**Hematologic:** Cyanosis secondary to methemoglobinemia has been reported rarely.

**Miscellaneous:** As with other antimicrobial agents, superinfections caused by resistant organisms, e.g., *Pseudomonas* species or *Candida* species, can occur.

**Laboratory Adverse Events:** The following laboratory adverse events have been reported with the use of nitrofurantoin: increased AST (SGOT), increased ALT (SGPT), decreased hemoglobin, increased serum phosphorus, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia (see **WARNINGS**), agranulocytosis, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia, megaloblastic anemia. In most cases, these hematologic abnormalities resolved following cessation of therapy. Aplastic anemia has been reported rarely.

**OVERDOSAGE:** Occasional incidents of acute overdosage of **Macrochantin** have not resulted in any specific symptoms other than vomiting. Induction of emesis is recommended. There is no specific antidote, but a high fluid intake should be maintained to promote urinary excretion of the drug. It is dialyzable.

**DOSAGE AND ADMINISTRATION:** **Macrochantin** should be given with food to improve drug absorption and, in some patients, tolerance.

**Adults:** 50-100 mg four times a day -- the lower dosage level is recommended for uncomplicated urinary tract infections.

**Pediatric Patients:** 5-7 mg/kg of body weight per 24 hours, given in four divided doses (contraindicated under one month of age).

Therapy should be continued for one week or for at least 3 days after sterility of the urine is obtained. Continued infection indicates the need for reevaluation.

**Macrochantin (nitrofurantoin macrocrystals)**

For long-term suppressive therapy in adults, a reduction of dosage to 50-100 mg at bedtime may be adequate. For long-term suppressive therapy in pediatric patients, doses as low as 1 mg/kg per 24 hours, given in a single dose or in two divided doses, may be adequate. **SEE WARNINGS SECTION REGARDING RISKS ASSOCIATED WITH LONG-TERM THERAPY.**

**HOW SUPPLIED:** Macrochantin is available as follows:

25 mg opaque, white capsule imprinted with one black line encircling the capsule and coded "MACRODANTIN 25 mg" and "0149-0007."\*

**NDC 0149-0007-05** bottle of 100

50 mg opaque, yellow and white capsule imprinted with two black lines encircling the capsule and coded "MACRODANTIN 50 mg" and "0149-0008."\*

**NDC 0149-0008-05** bottle of 100

**NDC 0149-0008-67** bottle of 1000

100 mg opaque, yellow capsule imprinted with three black lines encircling the capsule and coded "MACRODANTIN 100 mg" and "0149-0009."\*

**NDC 0149-0009-05** bottle of 100

**NDC 0149-0009-67** bottle of 1000

\*Capsule design, registered trademark of Procter & Gamble Pharmaceuticals.

Rx Only

**REFERENCES:**

1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically -- Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December 1993.
2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests -- Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993.

**Procter & Gamble Pharmaceuticals**

Cincinnati, OH 45202

REVISED June 2003

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**16-620 / S-062**

**MICROBIOLOGY REVIEW(S)**



PROCTER & GAMBLE PHARMACEUTICALS  
MACRODANTIN CAPSULES

RELATED DOCUMENTS: 8-693; 20-064

CONSULTS: NA

MICROBIOLOGY REVIEW

INTRODUCTION: Macrofantin(nitrofurantoin) capsules are composed of nitrofurantoin macrocrystals. Macrofantin is an antibacterial agent for specific urinary tract infections. At therapeutic doses it is bactericidal in urine.

PRE-CLINICAL EFFICACY

SPECTRUM OF ACTIVITY AND MECHANISM(S) OF ACTION:

The spectrum of activity of nitrofurantoin includes the Gram-positive facultative anaerobes *Staphylococcus aureus*, enterococci(e.g. *Enterococcus faecalis*) and the Gram-negative facultative anaerobe *Escherichia coli*(2).

In vitro activity against the Gram-positive facultative anaerobes *Streptococcus agalactiae*, Group D streptococci, viridans group streptococci, and coagulase-negative staphylococci(including *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*) and the Gram-negative facultative anaerobes *Citrobacter amalonaticus*, *Citrobacter diversus*, *Citrobacter freundii*, *Klebsiella oxytoca*, and *Klebsiella ozaenae* has been demonstrated. The clinical significance of this in relation to treatment with nitrofurantoin is unknown. Nitrofurantoin is not active against most strains of *Proteus* species or *Serratia* species and has no activity against *Pseudomonas* species(2).

Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial proteins. As a result the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA and RNA synthesis, and cell wall synthesis are inhibited leading to the death of the bacterial cell(3,4,5). Because nitrofurantoin has a multi-targeted approach to killing bacterial cells development of resistance to nitrofurantoin occurs at a low frequency(4).

MECHANISMS OF RESISTANCE:

Bacteria resistant to nitrofurantoin have been shown to have reductions in nitrofurantoin reductase activity. The reductase enzyme is the oxygen-insensitive, reduced nicotinamide adenine dinucleotide-linked form of the enzyme, thereby reducing the production of active derivatives of nitrofurantoin(4).

EPIDEMIOLOGY

Development of resistance to nitrofurantoin has not been a problem since its introduction in 1953(2,6,7,8). This low incident of development of resistance is believed to be due to the multi-site attack on the bacterial cell(4)

MICROBIOLOGY DATA SUBMITTED: Volume 1 of 1.

DOSAGE: 25mg or 50mg or 100mg

PHARMOKINETICS/BIOAVAILABILITY

Nitrofurantoin is orally administered and readily adsorbed and rapidly excreted in urine. The presence of food or agents delaying gastric emptying can increase the bioavailability of nitrofurantoin presumably by allowing better dissolution in gastric juices. Tubular reabsorption of nitrofurantoin is pH-dependent. An acid urine will promote the renal tubular reabsorption of nitrofurantoin, resulting in an increase in drug concentration in the renal lymph. In the presence of an alkaline urine, tubular reabsorption is decreased yielding an increased concentration of nitrofurantoin in the bladder(9). Blood concentrations are usually low(2).

CLINICAL EFFICACY

Clinical Microbiology

The labeling changes submitted by this NDA holder(8/20/96) do not change:

- 1) previously approved indications
- 2) susceptibility test disc concentration

**PROCTER & GAMBLE PHARMACEUTICALS  
MACRODANTIN CAPSULES**

- 3) MIC or zone size interpretive criteria
- 4) quality control criteria and
- 5) a review of the recent literature (see references cited) did not reveal any information which would indicate that the number of resistant organisms to nitrofurantoin or cross resistance has increased substantially since 1953.

These labeling changes do not make any additional claims as to the spectrum of activity of this antimicrobial or the bacteriological efficacy of the antimicrobial.

**STUDIES SUBMITTED:**

No studies were submitted with this NDA.

**MICROBIOLOGY PHARMOKINETICS:**

No new studies were submitted addressing the pharmacokinetics of Macrochantin. See page 3 of this review.

**DEVELOPMENT OF RESISTANCE:**

No new studies were submitted with this NDA addressing the development of resistance to Macrochantin. See page 3 of this review.

**REMARKS/COMMENTS:**

This submission is for a labeling change requested by the FDA in a letter dated August 28, 1995 for the new drug application, Macrochantin(nitrofurantoin) capsules, NDA #16-620.

**CONCLUSIONS AND RECOMMENDATIONS:**

The changes made to the "Susceptibility Test" portion of the package insert are in accordance with the current FDA/CDER guidance documents. The "Microbiology" content of the package insert is in accordance with currently accepted thinking and practice as it relates to the use of nitrofurantoin in the treatment of urinary tract infection. A literature search did not

PROCTER & GAMBLE PHARMACEUTICALS  
MACRODANTIN CAPSULES

reveal any substantial change in development of resistance to nitrofurantoin.

## REFERENCES

1. Nitrofurantoin U.S.P.. 1996. U.S.P. Dictionary of USAN and International Drug Names. US Pharmacopieal Convention, Inc., Rockville, MD.
2. Hopper, D.C. 1995. Urinary tract agents: Nitrofurantoin and methenamine, p. 376-381. In G.L. Mandell, J.E. Bennett, R. Dolin(ed.), Principles and Practice of Infectious Diseases, 4th ed., Churchill Livingstone, NY.
3. McCalla, D.R., A. Reuvers, and C. Kaiser. 1970. Mode of action of nitrofurazone. J. Bacteriol. 104:1126-1134.
4. McOsker, C.C., and P.M. Fitzpatrick. 1994. Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens. J. Antimicrobial Chemotherapy 33:23-30.
5. Yu, T., D.R. McCalla. 1975. Effect of activated nitrofurans on DNA. Biochemica et Biophysica Acta 402:142-149.
6. Thomson, K.S., W.E. Sanders, and C.C. Sanders. 1994. USA resistance patterns among UTI pathogens. J. Antimicrobial Chemotherapy 33:9-15.
7. Ansbach, R.K., K.R. Dybus, and R. Bergson. 1995. Uncomplicated *E. coli* urinary tract infection in college women: A retrospective study of *E. coli* sensitivities to commonly prescribed antibiotics. J. Amer. College Health 43:183-185.
8. Bint, A.J., and D. Hill. 1994. Bacteriuria of pregnancy - an update on significance, diagnosis and management. J. Antimicrobial Chemotherapy 33:93-97.
9. Comer, J.B., P.A. Ristuccia, M.D. Beltran, et al. 1984. Urine, p. 487-496. In A.M Ristuccia, B.A. Cunha(ed.), Antimicrobial Therapy, Raven Press, NY.

NDA 16-620  
PROCTER & GAMBLE PHARMACEUTICALS  
MACRODANTIN CAPSULES

PAGE 6 of 6

*Frederic J. Marsik* 5/19/97

Frederic J. Marsik, Ph.D.  
Microbiology Reviewer

cc: Original NDA#: 16-620  
HFD-520 Division File  
HFD-520/MO/R.Viraraghavan  
HFD-520/Chem/D.Katagne  
HFD-520/Pharm/Tox/R.Osterberg  
HFD-520/Micro/F.Marsik  
HFD-520/CSO/Duvall-Miller

**Concurrence Only**

HFD-520/Dep/Dir/L.Gavrilovich  
HFD-520/GLMicro/ATSheldon

72 5/20/97

*LB* 6/14/97